[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2015056259A1 - Système et procédé pour une gestion améliorée de pancréas artificiel - Google Patents

Système et procédé pour une gestion améliorée de pancréas artificiel Download PDF

Info

Publication number
WO2015056259A1
WO2015056259A1 PCT/IL2014/050886 IL2014050886W WO2015056259A1 WO 2015056259 A1 WO2015056259 A1 WO 2015056259A1 IL 2014050886 W IL2014050886 W IL 2014050886W WO 2015056259 A1 WO2015056259 A1 WO 2015056259A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
time
meal
bolus
level
Prior art date
Application number
PCT/IL2014/050886
Other languages
English (en)
Inventor
Revital Nimri
Eran Atlas
Shahar Miller
Ido MULLER
Moshe Phillip
Aviel FOGEL
Original Assignee
Dreamed-Diabetes Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dreamed-Diabetes Ltd. filed Critical Dreamed-Diabetes Ltd.
Publication of WO2015056259A1 publication Critical patent/WO2015056259A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/201—Glucose concentration

Definitions

  • the present invention relates generally to computerized health systems and in particular to computerized dosage administration.
  • Meal treatment is a challenging task in type 1 diabetes management.
  • the use of different artificial pancreas systems could not completely eliminate the frequently found postprandial glucose excursions above the target range. This happens mainly due to a delay in subcutaneous insulin absorption and action.
  • a more aggressive insulin treatment for meals together with the use of artificial pancreas system might reduce the glucose excursion, but may, on the other hand, cause postprandial hypoglycemia, due to the lack of counter-regulatory means to control low blood glucose.
  • hybrid closed-loop control means giving manual pre-meal bolus of insulin to cover the meal (1-3).
  • Various techniques have been developed aimed at helping the patient to compute the amount of insulin needed in order to cover the meal consumed. In most of them, the computation is based on a prior knowledge of the patient Carbohydrates Ratio (CR), the reported carbohydrates consumption and the current
  • the CR might change between days and even within the same day.
  • meals with different glycemic index may need a different way to compute the amount of insulin as well as the type of insulin bolus to cover the meal.
  • the calculators are based on a single glucose level measured by a glucometer. This input is lacking the time factor - data that can be provided by a continuous glucose sensor. Thus, the glucose trends before the meal and prediction of glucose post meal may also be taken into consideration when computing the meal bolus.
  • the method of the insulin pump's bolus calculator is based on the assumption that the patient cannot continuously track his glucose level and give additional correction dosing if necessary.
  • This MD-Logic Bolus Calculator may automatically adjust the patient's carbohydrate ratio (CR- ratio that relates between amount of carbohydrates consumed to insulin and the patient basal insulin dosing) and/or correction factor (CF - amount of insulin injection affecting the glucose level) for the pre-meal bolus dosing computation and may also take into account some or all of: the glucose trends before the meal, glucose prediction, previous insulin delivery and amount of carbohydrate consumed.
  • CR- ratio that relates between amount of carbohydrates consumed to insulin and the patient basal insulin dosing
  • CF - amount of insulin injection affecting the glucose level correction factor
  • Monitoring typically takes into account inputs entered to the calculator by the user such as but not limited to some or all of: the amount of carbohydrates consumed, other ingredients of the meal (e.g. percentage of fat and/or protein), specific event patient is participating in, function of a specific time of day (e.g. sleep, meal, exercise, disease).
  • the calculator may present the user with pre-programmed meals including details of ingredients.
  • the processor utility typically analyzes glucose history measurements to produce suitable parameter/s such as past trend of glucose levels and typically utilizes a suitable conventional prediction model for predicting glucose level in blood based on measured glucose level.
  • the bolus calculator output typically combines available inputs to determine appropriate insulin dosing for the meal.
  • Certain embodiments seek to provide a method for monitoring diabetes treatment and a system for use in monitoring diabetes treatment of a patient connected to an artificial pancreas.
  • Certain embodiments seek to provide a method for computing an insulin dose to cover a meal assuming a patient is under artificial pancreas treatment, such that for a patient on artificial pancreas treatment a more aggressive regimen of basal/bolus insulin delivery (Giving more insulin than conventional treatment guidelines might recommend for a specific data sets of glucose/history of insulin etc.) may be employed to compensate for the consumed carbohydrate and achieve tighter control without increasing hypoglycemia events e.g. by: a. considering the data from the glucose continuous sensor, the glucose level during the meal and the trends of the glucose in the past & future in order to tune the insulin dosing; and/or
  • glucose may be kept at all times within or close to a safe range of glucose levels e.g. 80-120 mg/dl.
  • Conventional advisors for insulin dosing for meals e.g. software features available in insulin pumps and related applications may use the discrete glucose level measured using a glucometer and may not use continuous glucose sensor data.
  • Certain embodiments seek to provide a method for computing meal bolus as function of (inter alia) glucose trends assuming the patient is under artificial pancreas treatment.
  • glucose trends is intended to include glucose rate of change typically accompanied by data characterizing the duration for which a specific rate of change lasts. For example, perhaps in a first data point the rate of change of glucose is -2 mg/dl/min which rate of change lasts for 3 minutes. Then, in a second data point, the rate of change of glucose is -2 mg/dl/min which rate of change lasts for 3 hours. In this case, the trend of the first data point is similar vis a vis rate of change but the trend of the second data point is smaller than - 2mg/dl/min (for example -4mg/dl/min) since that rate of change endures for a long period of time.
  • - 2mg/dl/min for example -4mg/dl/min
  • Certain embodiments seek to provide a method for increasing insulin dosage relative to the amount of insulin conventional treatment guidelines might recommend for the same meal based on the same data sets of glucose/history of insulin. ) and for achieving lower post - meal glucose levels relative to conventionally recommended post meal glucose levels after delivering the amount of insulin conventionally recommended as a dose for a
  • embodiments seek to provide a method for computing an insulin dose (bolus) to cover a meal consumed by a patient on artificial pancreas treatment, the method comprising computing (and delivering) a level of insulin to be delivered, by Receiving continuous glucose level data series from a continuous glucose level sensor during the meal; Using a processor for Identifying the impact of glucose dynamics in said continuous glucose level data series on the amount of insulin needed for the meal; and determining said insulin level based on said dynamics.
  • the method may also comprise additional insulin dosing which is equivalent to the basal insulin dosage for a certain period of time ahead
  • trends are identified from the raw data of the glucose in the past & future in order to tune insulin dosing.
  • Predictive glucose levels may be generated for several minutes ahead (e.g. 30-60 minutes ahead).
  • the predictive glucose is an indicator of the past and current glucose levels and may be computed by taking the current glucose level and using a predictive trend to find the predictive glucose level at a certain time ahead.
  • basal insulin treatment is loaded on top of computation of the meal bolus in order to increase the amount of insulin dosage and achieve lower post - meal glucose levels.
  • the Post meal period is approximately 2 hours post meal. Diabetes patients are conventionally given a physician-determined "basal" rate of insulin in order to compensate for the internal production of glucose by the liver.
  • patient takes the amount of overall insulin dosage of the basal rate the patient is to receive during the post meal period (e.g 2 hours post meal) and delivers the same amount as a bolus at meal time.
  • Inputs may be entered by the user such as ingredients of the meal e.g. percentage of fat and protein, which may for example be obtainable by looking at the table of ingredients in the food's packaging, or by using available tables which allow the patient to see ingredients in different types of food.
  • ingredients of the meal e.g. percentage of fat and protein, which may for example be obtainable by looking at the table of ingredients in the food's packaging, or by using available tables which allow the patient to see ingredients in different types of food.
  • Pre-meal bolus dosing computation may take into account a specific event that the patient is in or is about to be in, e.g. as a function of a specific time of day (as sleep, meal, exercise, disease). For example, different CR and CF values may be set as a function of the specific time of day or event. For example, if the patient is doing exercise, the insulin sensitivity of the patient may change resulting in different CF and CR values being used in computations described herein.
  • Embodiment 1 A method, system or computer program product for delivering insulin, the method comprising Using a processor for computing a level of insulin to be delivered to an individual patient using an artificial pancreas, as a bolus before a meal, including determining a total dose which would have been administered for a predetermined window of time following the meal; administering the bolus; and refraining from administering at least a portion of said total dose during said predetermined window of time and instead adding said at least a portion to said level of insulin delivered as a bolus in said administering step.
  • Embodiment 2 A method according to Embodiment 1 and also comprising: receiving continuous glucose level data for the individual patient from a continuous glucose level sensor prior to said window of time and using a processor to generate a predicted glucose level during said window of time irrespective of the meal based on said glucose level data; and
  • determining said level of insulin delivered as a bolus in said administering step by combining said at least a portion of said total dose with an insulin level suitable for said predicted glucose level.
  • Embodiment 3 A method according to Embodiment 1 and also comprising taking at least one meal ingredient into account for said determining.
  • Embodiment 4 A method according to Embodiment 1 wherein said refraining comprises entirely refraining from administering said total dose (zero basal rate), during said predetermined window of time and wherein said at least a portion of said total dose comprises the entirety of said total dose.
  • Embodiment 5 A method according to Embodiment 1 wherein said bolus is administered before the meal.
  • Embodiment 6 A method according to Embodiment 1 wherein said window of time comprises a period of time whose length is within a range of 1.25 - 3.5 hours.
  • Embodiment 7 A method according to Embodiment 1 wherein said window of time comprises a period of time whose length is within a range of 1.5 - 3 hours.
  • Embodiment 8 A method according to Embodiment 1 wherein said window of time comprises a period of time whose length is within a range of 1.75 - 2.5 hours.
  • Embodiment 9 A method according to Embodiment 1 wherein said window of time comprises a period of time whose length is 2 hours.
  • Embodiment 10 A method according to Embodiment 1 wherein the total dose which would have been administered for a predetermined window of time following the meal is determined based on a basal plan currently followed by said individual patient's artificial pancreas.
  • Embodiment 11 A method according to Embodiment 2 wherein said predicted glucose level is generated using linear interpolation.
  • Embodiment 12 A method according to Embodiment 2 wherein said predicted glucose level is generated using an autoregression model.
  • Embodiment 13 A method according to Embodiment 2 wherein said insulin level suitable for said predicted glucose level is negative and said combining comprises subtracting said insulin level from said at least a portion of said total dose.
  • the autoregression model used to generate the predicted glucose level may for example be as described in: J Diabetes Sci Technol. Sep 2007; 1(5): 645-651. Published online Sep 2007. doi: 10.1901/iaba.2007.1-645. Sensors & Algorithms for Continuous Glucose Monitoring - Glucose Prediction Algorithms from Continuous Monitoring Data:
  • a computer program product comprising a computer usable medium or computer readable storage medium, typically tangible, having a computer readable program code embodied therein, said computer readable program code adapted to be executed to implement any or all of the methods shown and described herein. It is appreciated that any or all of the computational steps shown and described herein may be computer-implemented. The operations in accordance with the teachings herein may be performed by a computer specially constructed for the desired purposes or by a general purpose computer specially configured for the desired purpose by a computer program stored in a computer readable storage medium.
  • Any suitable processor, display and input means may be used to process, display e.g. on a computer screen or other computer output device, store, and accept information such as information used by or generated by any of the methods and apparatus shown and described herein; the above processor, display and input means including computer programs, in accordance with some or all of the embodiments of the present invention.
  • any or all functionalities of the invention shown and described herein may be performed by a conventional personal computer processor, workstation or other programmable device or computer or electronic computing device, either general-purpose or specifically constructed, used for processing; a computer display screen and/or printer and/or speaker for displaying; machine-readable memory such as optical disks, CDROMs, magnetic-optical discs or other discs; RAMs, ROMs, EPROMs, EEPROMs, magnetic or optical or other cards, for storing, and keyboard or mouse for accepting.
  • the term "process” as used above is intended to include any type of computation or manipulation or transformation of data represented as physical, e.g. electronic, phenomena which may occur or reside e.g. within registers and /or memories of a computer.
  • a computer program comprising computer program code means for performing any of the methods shown and described herein when said program is run on at least one computer; and a computer program product, comprising a typically non- transitory computer-usable or -readable medium e.g. non-transitory computer -usable or - readable storage medium, typically tangible, having a computer readable program code embodied therein, said computer readable program code adapted to be executed to implement any or all of the methods shown and described herein.
  • the operations in accordance with the teachings herein may be performed by at least one computer specially constructed for the desired purposes or general purpose computer specially configured for the desired purpose by at least one computer program stored in a typically non-transitory computer readable storage medium.
  • the term "non-transitory” is used herein to exclude transitory, propagating signals or waves, but to otherwise include any volatile or non-volatile computer memory technology suitable to the application.
  • processor/s, display and input means may be used to process, display e.g. on a computer screen or other computer output device, store, and accept information such as information used by or generated by any of the methods and apparatus shown and described herein; the above processor/s, display and input means including computer programs, in accordance with some or all of the embodiments of the present invention.
  • any or all functionalities of the invention shown and described herein, such as but not limited to steps of flowcharts, may be performed by at least one conventional personal computer processor, workstation or other programmable device or computer or electronic computing device or processor, either general-purpose or specifically constructed, used for processing; a computer display screen and/or printer and/or speaker for displaying; machine-readable memory such as optical disks, CDROMs, DVDs, BluRays, magnetic-optical discs or other discs; RAMs, ROMs, EPROMs, EEPROMs, magnetic or optical or other cards, for storing, and keyboard or mouse for accepting.
  • the term "process” as used above is intended to include any type of computation or manipulation or transformation of data represented as physical, e.g. electronic, phenomena which may occur or reside e.g. within registers and /or memories of at least one computer or processor.
  • processor includes a single processing unit or a plurality of distributed or remote such units.
  • the above devices may communicate via any conventional wired or wireless digital communication means, e.g. via a wired or cellular telephone network or a computer network such as the Internet.
  • the apparatus of the present invention may include, according to certain embodiments of the invention, machine readable memory containing or otherwise storing a program of instructions which, when executed by the machine, implements some or all of the apparatus, methods, features and functionalities of the invention shown and described herein.
  • the apparatus of the present invention may include, according to certain embodiments of the invention, a program as above which may be written in any conventional programming language, and optionally a machine for executing the program such as but not limited to a general purpose computer which may optionally be configured or activated in accordance with the teachings of the present invention. Any of the teachings incorporated herein may wherever suitable operate on signals representative of physical objects or substances.
  • Fig. 1 is a schematic diagram of a treatment system utilizing an artificial pancreas system
  • Fig. 2 is a schematic diagram of a treatment system utilizing an artificial pancreas system together with a bolus calculator
  • Fig. 3 is a simplified flow diagram of a method for monitoring a diabetes treatment of a patient.
  • Flowchart steps typically comprises some or all of the steps illustrated, suitably ordered e.g. as shown.
  • Fig. 1 is a simplified block diagram of an artificial pancreas system 10 for carrying out diabetes treatment including controllable delivery of insulin and glucagon).
  • the artificial pancreas system 10 may be associated with a glucose measurement device 12 (e.g. continuous glucose sensor), and a drug delivery device 14 (e.g. insulin/glucagon delivery pumps).
  • Measured blood glucose (BG) level from measurement device 12 whether directly measured or predicted from measured tissue glucose level, enters , e.g. through a communication dongle 16, a data processing and analyzing utility 20 of the artificial pancreas.
  • Measured data may also include activity diary, such as meals, physical activity, sleep time etc.
  • a treatment recommendation may be sent, e.g. through a communication dongle 16, to a delivery device 14.
  • Fig. 2 is a simplified block diagram illustration of an artificial pancreas system 10 for carrying out diabetes treatment e.g. controllable delivery of insulin and glucagon, utilizing a monitoring system 20 and a bolus calculator 30 as per embodiments of the present invention.
  • the monitoring system 20 may be associated with a glucose measurement device 12 e.g. continuous glucose sensor and a drug delivery device 14 e.g. insulin/glucagon delivery pumps.
  • Measured blood glucose (BG) level, BG aorent , from measurement device 12 may be either directly measured or predicted from measured tissue glucose level and enters a data processing and analyzing utility 23 of the monitoring system (aka the control algorithm) and also, typically, a memory utility 22 for storage and/or update of reference data, e.g. patient's profile related data and possibly also Zog-utility relating to treatment history data. Additional measured data such as but not limited to: time of day, meals description e.g. amount of carbohydrates (CHO), percentage of protein (P), percentage of fat (F), human selection of a specific meal description from a list, physical activity (PA) whether accomplished or planned, sleep time, and presence of illness may be entered into the memory utility 22 by the user using a suitable user interface 24.
  • CHO amount of carbohydrates
  • P percentage of protein
  • F percentage of fat
  • PA physical activity
  • the bolus calculator 30 may, e.g. as shown herein, recommend a required amount of insulin in order to compensate for a consumed meal.
  • the bolus calculator which may comprise a processor utility, may operate data available in the memory utility 22 and may analyze the glucose history measurement to produce several parameters such as glucose rate of change.
  • the bolus calculator 30 may also utilize a prediction model such as but not limited to an auto-regressive model for prediction of glucose levels for predicting the glucose level based on the measured history of glucose level.
  • the bolus calculator 30 may also use the history of insulin delivery to compute the amount of insulin on board I active .
  • the bolus calculator 30 output may be produced after considering all possible inputs to determine the appropriate insulin dosing for the meal based e.g. on the caring physician's approach to decision making vis a vis a specific patient under treatment and may control further treatment accordingly.
  • the meal bolus recommendation may for example be a combination of:
  • B CHOi is may be computed as a function of one or more of: the amount of carbohydrates that the patient consumed (CHO), the patient specific carbohydrate ratio (CR), the amount of the percentage of protein (P),
  • B CHOi p may for example be:
  • k is an empirically determined scaling factor to conventional insulin dosage computation to cover for CHO consumption.
  • A may for example be equal to 0.8 .
  • 3 ⁇ 4G Dynamics the amount of insulin computed to fine tune a given bolus according to glucose dynamics and projected patient events (if entered) at the time of the meal.
  • Glucose dynamics may be characterized by one or more of: current glucose level ( BG MMNT ), glucose rate of change computed based on the history of measured glucose
  • B BGJ BGJynarnics
  • BBG .Dynamics may be positive.
  • B BG Dynamics may be a function of the current glucose level ( BG ⁇ M ), a multiplier corresponding to the glucose dynamics ( P BOLUS ), the glucose target (7), the patient's correction factor (CF) and the history of insulin delivery to compute the amount of insulin on board I ACTJVE , e.g. as follows:
  • BBG_Dynamics f(S> ⁇ bolus' ⁇ ⁇ ⁇ > ⁇ active)
  • P 3 ⁇ 40 j us may also be limited to a certain range of acceptable ratios between BG Predicted and BGcurrent ⁇
  • a reasonable range to limit P bo i us may be between 0.6 to 1.2.
  • B BG_Dynamics ma y have positive or negative values.
  • the value of B BG Dynamics may be limited to a certain percentage of B CH0 P , to avoid cases where B BG Dyna mics has too much effect on the amount of insulin required for the consumed carbohydrates.
  • a reasonable limit of B BG Dynamtcs may for example be +/-20% of B CH0 P .
  • B basal is the amount of basal insulin the patient is to receive for a period of 1.5-3.5 hours ahead, which according to certain embodiments is administered as a bolus instead whereas during the above period the basal treatment for the patient may be zero, if all of the basal dosing was delivered as bolus or may be reduced, if some of the basal dosing was delivered as bolus.
  • the bolus calculator 30 may also recommend a suitable pre-programmed dosing strategy of B meal , e.g. as immediate bolus, square bolus or dual bolus, generated using conventional guidelines for selecting dosing strategy typically as a function of ingredients of the meal.
  • a suitable pre-programmed dosing strategy of B meal e.g. as immediate bolus, square bolus or dual bolus, generated using conventional guidelines for selecting dosing strategy typically as a function of ingredients of the meal.
  • the B meal and the output of the control algorithm 23 may be processed by a treatment jury module 31 such as that described in co-pending US 2012/0123234 entitled "method and system for automatic monitoring of diabetes related treatments".
  • the control algorithm recommendation may be related to the correction of the patient's current glucose level e.g. as described in co-pending US 2012/0123234 entitled “method and system for automatic monitoring of diabetes related treatments”.
  • Safety considerations may be used to provide optimal insulin dosing without risking the patient.
  • the final decision relating data from the treatment jury module 31 may be used for updating reference data (treatment history) e.g. in a Zog-utility and may be sent to the delivery device 14 and/or presented in the user interface 24.
  • Certain embodiments seek to provide a bolus calculator comprising a computerized advisor whose processor is operative for providing individualized insulin dosing to cover meals, and comprises inter alia some or all of memory utility, data processing and analyzing utility, and a processor utility.
  • the bolus calculator is typically operable as a feature within an artificial pancreas system, e.g. as described in co-pending US 2012/0123234 entitled "method and system for automatic monitoring of diabetes related treatments". Therefore the bolus calculator may be operative in conjunction with any or all of the following:
  • a first processor module for processing measured data indicative of blood glucose level and generating first processed data indicative thereof
  • a second processor module (which may serve as the treatment jury module 31) comprising at least one fuzzy logic module; said fuzzy logic module receives input parameters corresponding to the measured data, the first processed data and a reference data including individualized patient's profile related data, individualized patient's treatment history related data, processes the received parameters to produce at least one qualitative output parameter indicative of patient's treatment parameters; such that said second processor module determines whether any of the treatment parameters is to be modified.
  • obtaining a reference data including individualized patient's profile related data, individualized patient's treatment history related data
  • the method of claim 43 in co-pending US 2012/0123234 for determining insulin basal plan from a series of basal treatment rates for a patient in need thereof, comprises:
  • a monitoring system of co-pending US 2012/0123234 for use in monitoring diabetes treatment of a patient comprising: a control unit comprising
  • a first processor module for processing measured data indicative of blood glucose level and generating first processed data indicative thereof
  • a second processor module comprising at least one fuzzy logic module; said fuzzy logic module receives input parameters corresponding to the measured data, the first processed data and a reference data including individualized patient's profile related data, individualized patient's treatment history related data and a structure of rules setting, applies at least one fuzzy logic model to quantitative input parameters corresponding to the measured data, the first processed data by using the structure of rules setting to produce at least one qualitative output parameter indicative of patient's treatment parameters;
  • a third processor module (which may serve as the treatment jury module 31) for determining a current amount of glucagon and/or insulin active section in the blood according to the patient's profile, and determining the amounts of insulin and/or glucagon to be delivered based on the at least one qualitative output parameter received from the second processor module, the patient's treatment history, the insulin/glucagon sensitivity from the patient profile and the current amount of glucagon and/or insulin active section in the blood.
  • the bolus calculator may be am input to a memory utility of an artificial pancreas and/or may communicate with other sensing devices.
  • the bolus calculator may be used: for processing measured data from any known suitable measurement device for measuring blood/tissue glucose levels and/or for computing amount of insulin dosing only.
  • Certain embodiments seek to provide a bolus calculator which utilizes a specific bolus calculator to be used considering a closed-loop analysis of measured data. Analysis may be based on the physician approach for decision making with respect to a specific patient under treatment and controlling the further treatment accordingly.
  • Processing of the measured data typically utilizes inputs measured automatically together with inputs provided to the calculator by the user.
  • Possible automatic inputs may include some or all of: the history of glucose measurements, the history of treatment for the specific patient, the time of the day (e.g. morning, lunch or evening) and the patient's profile (e.g. some or all of: sensitivity to insulin injection, the ratio that relates between amount of carbohydrates consumed to insulin and the patient basal insulin dosing).
  • the treatment history related data may include for example insulin basal rate given to the patient at different hours of the day and insulin bolus dosing.
  • the patient's profile related data may include a set of previously computed (and calibratable or updatable during the treatment) parameters about the patient's condition with respect to a treatment, such as at least one of a response time to insulin absorption, sensitivity to insulin, CF, and the CR) all typically being a function of time and patient's current condition depending on his/her activity.
  • the system typically utilizes the patient's profile, which includes a set of calibratable/updatable parameters and typically applies a self-learning approach for updated the patient's profile based on the executed treatment e.g. using any suitable learning process such as those described in co-pending US 2012/0245106 entitled "monitoring device for management of insulin delivery".
  • the system herein may therefore be used in conjunction with any or all of the following:
  • a communication interface configured and operable to permit access to stored raw log data obtained over a certain time and being time spaced data points of glucose measurements, meals consumed and insulin delivery;
  • control unit configured for receiving and processing said raw log data, the control unit comprising:
  • a sectioning module configured sectioning the raw log data within a time window; the sectioned time window having a starting point and an end point being at least one of Basal data Section (BaS); Meals data Section (MS) and Bolus data Section (BS), the BaS being selected outside an effect window of either meal or bolus, the MS being selected at a predetermined time ahead a meal data point, and the starting point of the BS being selected as one of the following: the end point of the MS or the BaS, and an insulin bolus data point which is outside the MS; the end point of the BS being selected as one of the following, the starting point of the MS or BaS and a predetermined time ahead of insulin bolus data point without any bolus insulin;
  • Basal data Section BaS
  • MS Meals data Section
  • BS Bolus data Section
  • an unsupervised learning controller configured and operable to determine an informative data piece from residual log data portion of said raw log data, analyzing said informative data piece and selecting a sectioned time window for calculation of individualized patient's profile related data comprising at least one global insulin pump setting of basal rate, correction factor (CF), carbohydrate ratio (CR) and insulin activity curve parameters, wherein the BaS enables to calculate basal rate, the MS enables to calculate at least one of insulin activity curve parameters, correction factor (CF) and carbohydrate ratio (CR) and the BS enables to calculate correction factor (CF) or insulin activity curve parameters.
  • said unsupervised learning comprising:
  • AIF Active Insulin Function
  • the raw log data being indicative of glucose measurements, meals events and insulin delivery of the patient;
  • the raw log data being sectioned, containing data obtained at a time section;
  • the control unit of claim 44 of co-pending US 2012/0245106 for use with diabetic treatment management comprising: a data processor utility configured and operable as an unsupervised learning controller preprogrammed for processing raw log data input obtained over a certain time and being indicative of glucose measurements, meals events and insulin delivery, said processing comprising determining an informative data piece from residual log data portion of said raw log data and selecting said informative data piece for further processing to determine at least one of basal rate, correction factor (CF), carbohydrate ratio (CR) and insulin activity curve parameters, and sectioning the raw log data within a predetermined time window; the predetermined time window being at least one of Basal data Section (BaS); Meals data Section (MS) and Bolus data Section (BS) and generating global insulin pump settings wherein different insulin pump settings' are acquired at different selected time windows in said certain time.
  • Basal data Section Basal data Section
  • MS Meals data Section
  • BS Bolus data Section
  • the computer program of claim 45 of co-pending US 2012/0245106 recordable on a storage medium and comprising a machine readable format, the computer program being configured and operable to, when being accesses, carry out the following: identifying raw log data input corresponding to a certain time period and comprising glucose measurements, meals events and insulin delivery; determining an informative data piece and residual log data portion of said raw log data; sectioning the raw log data within a predetermined time window; the predetermined time window being at least one of Basal data Section (BaS); Meals data Section (MS) and Bolus data Section (BS) selecting said informative data piece and calculating therefrom at least one of basal rate, correction factor (CF), carbohydrate ratio (CR) and insulin activity curve parameters, and generating output data comprising values for global insulin pump settings wherein different insulin pump settings' are acquired at different selected time windows in said certain time.
  • Basal data Section Basal data Section
  • MS Meals data Section
  • BS Bolus data Section
  • software components of the present invention including programs and data may, if desired, be implemented in ROM (read only memory) form including CD- ROMs, EPROMs and EEPROMs, or may be stored in any other suitable computer-readable medium such as but not limited to disks of various kinds, cards of various kinds and RAMs.
  • ROM read only memory
  • EPROMs electrically erasable programmable read-only memory
  • EEPROM electrically erasable programmable read only memory
  • RAM random access memory
  • Components described herein as software may, alternatively, be implemented wholly or partly in hardware, if desired, using conventional techniques.
  • components described herein as hardware may, alternatively, be implemented wholly or partly in software, if desired, using conventional techniques.
  • Any computations or other forms of analysis described herein may be performed by a suitable computerized method. Any step described herein may be computer-implemented.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

L'invention concerne un procédé pour administrer de l'insuline, comprenant l'utilisation d'un processeur pour calculer un niveau d'insuline à administrer à un patient individuel en utilisant un pancréas artificiel, comme un bolus avant un repas, consistant à déterminer une dose totale qui devrait être administrée pendant une fenêtre de temps prédéterminée suivant le repas; administrer le bolus; et s'abstenir d'administrer au moins une partie de ladite dose totale pendant ladite fenêtre de temps prédéterminée, et ajouter à la place ladite au moins une partie audit niveau d'insuline.
PCT/IL2014/050886 2013-10-14 2014-10-07 Système et procédé pour une gestion améliorée de pancréas artificiel WO2015056259A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361890351P 2013-10-14 2013-10-14
US61/890,351 2013-10-14

Publications (1)

Publication Number Publication Date
WO2015056259A1 true WO2015056259A1 (fr) 2015-04-23

Family

ID=52827749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2014/050886 WO2015056259A1 (fr) 2013-10-14 2014-10-07 Système et procédé pour une gestion améliorée de pancréas artificiel

Country Status (1)

Country Link
WO (1) WO2015056259A1 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974903B1 (en) 2016-05-02 2018-05-22 Dexcom, Inc. System and method for providing alerts optimized for a user
CN112236826A (zh) * 2018-05-04 2021-01-15 英赛罗公司 基于控制算法的药物输送系统的安全约束
WO2021163179A1 (fr) * 2020-02-11 2021-08-19 Insulet Corporation Détection de repas précoce et détection d'absorption de calories
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11386996B2 (en) 2014-01-30 2022-07-12 Insulet Netherlands B.V. Therapeutic product delivery system and method of pairing
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
US11596740B2 (en) 2015-02-18 2023-03-07 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US11724027B2 (en) 2016-09-23 2023-08-15 Insulet Corporation Fluid delivery device with sensor
US11723560B2 (en) 2018-02-09 2023-08-15 Dexcom, Inc. System and method for decision support
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11857763B2 (en) 2016-01-14 2024-01-02 Insulet Corporation Adjusting insulin delivery rates
US11865299B2 (en) 2008-08-20 2024-01-09 Insulet Corporation Infusion pump systems and methods
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11929158B2 (en) 2016-01-13 2024-03-12 Insulet Corporation User interface for diabetes management system
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
USD1020794S1 (en) 2018-04-02 2024-04-02 Bigfoot Biomedical, Inc. Medication delivery device with icons
US11957875B2 (en) 2019-12-06 2024-04-16 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
USD1024090S1 (en) 2019-01-09 2024-04-23 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11969579B2 (en) 2017-01-13 2024-04-30 Insulet Corporation Insulin delivery methods, systems and devices
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US12036389B2 (en) 2020-01-06 2024-07-16 Insulet Corporation Prediction of meal and/or exercise events based on persistent residuals
US12042630B2 (en) 2017-01-13 2024-07-23 Insulet Corporation System and method for adjusting insulin delivery
US12064591B2 (en) 2013-07-19 2024-08-20 Insulet Corporation Infusion pump system and method
US12076160B2 (en) 2016-12-12 2024-09-03 Insulet Corporation Alarms and alerts for medication delivery devices and systems
US12097355B2 (en) 2023-01-06 2024-09-24 Insulet Corporation Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation
US12106837B2 (en) 2016-01-14 2024-10-01 Insulet Corporation Occlusion resolution in medication delivery devices, systems, and methods
US12115351B2 (en) 2020-09-30 2024-10-15 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
US12121700B2 (en) 2020-07-22 2024-10-22 Insulet Corporation Open-loop insulin delivery basal parameters based on insulin delivery records
US12121701B2 (en) 2021-01-29 2024-10-22 Insulet Corporation Systems and methods for incorporating co-formulations of insulin in an automatic insulin delivery system
US12128215B2 (en) 2020-09-30 2024-10-29 Insulet Corporation Drug delivery device with integrated optical-based glucose monitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080183060A1 (en) * 2007-01-31 2008-07-31 Steil Garry M Model predictive method and system for controlling and supervising insulin infusion
US20100249561A1 (en) * 2007-06-21 2010-09-30 University Of Virginia Patent Foundation LQG Artificial Pancreas Control System and Related Method
US20110257496A1 (en) * 2008-11-04 2011-10-20 Panasonic Corporation Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080183060A1 (en) * 2007-01-31 2008-07-31 Steil Garry M Model predictive method and system for controlling and supervising insulin infusion
US20100249561A1 (en) * 2007-06-21 2010-09-30 University Of Virginia Patent Foundation LQG Artificial Pancreas Control System and Related Method
US20110257496A1 (en) * 2008-11-04 2011-10-20 Panasonic Corporation Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865299B2 (en) 2008-08-20 2024-01-09 Insulet Corporation Infusion pump systems and methods
US12064591B2 (en) 2013-07-19 2024-08-20 Insulet Corporation Infusion pump system and method
US11386996B2 (en) 2014-01-30 2022-07-12 Insulet Netherlands B.V. Therapeutic product delivery system and method of pairing
US11596740B2 (en) 2015-02-18 2023-03-07 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
US11929158B2 (en) 2016-01-13 2024-03-12 Insulet Corporation User interface for diabetes management system
US11857763B2 (en) 2016-01-14 2024-01-02 Insulet Corporation Adjusting insulin delivery rates
US12106837B2 (en) 2016-01-14 2024-10-01 Insulet Corporation Occlusion resolution in medication delivery devices, systems, and methods
US10737025B2 (en) 2016-05-02 2020-08-11 Dexcom, Inc. System and method for providing alerts optimized for a user
US10406287B2 (en) 2016-05-02 2019-09-10 Dexcom, Inc. System and method for providing alerts optimized for a user
US10328204B2 (en) 2016-05-02 2019-06-25 Dexcom, Inc. System and method for providing alerts optimized for a user
US11450421B2 (en) 2016-05-02 2022-09-20 Dexcom, Inc. System and method for providing alerts optimized for a user
US11837348B2 (en) 2016-05-02 2023-12-05 Dexcom, Inc. System and method for providing alerts optimized for a user
US9974903B1 (en) 2016-05-02 2018-05-22 Dexcom, Inc. System and method for providing alerts optimized for a user
US10052073B2 (en) 2016-05-02 2018-08-21 Dexcom, Inc. System and method for providing alerts optimized for a user
US11724027B2 (en) 2016-09-23 2023-08-15 Insulet Corporation Fluid delivery device with sensor
US12076160B2 (en) 2016-12-12 2024-09-03 Insulet Corporation Alarms and alerts for medication delivery devices and systems
US12042630B2 (en) 2017-01-13 2024-07-23 Insulet Corporation System and method for adjusting insulin delivery
US11969579B2 (en) 2017-01-13 2024-04-30 Insulet Corporation Insulin delivery methods, systems and devices
US11723560B2 (en) 2018-02-09 2023-08-15 Dexcom, Inc. System and method for decision support
US11766194B2 (en) 2018-02-09 2023-09-26 Dexcom, Inc. System and method for decision support
USD1020794S1 (en) 2018-04-02 2024-04-02 Bigfoot Biomedical, Inc. Medication delivery device with icons
US12090301B2 (en) 2018-05-04 2024-09-17 Insulet Corporation Safety constraints for a control algorithm based drug delivery system
US11565043B2 (en) 2018-05-04 2023-01-31 Insulet Corporation Safety constraints for a control algorithm based drug delivery system
CN112236826A (zh) * 2018-05-04 2021-01-15 英赛罗公司 基于控制算法的药物输送系统的安全约束
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
USD1024090S1 (en) 2019-01-09 2024-04-23 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
US11957875B2 (en) 2019-12-06 2024-04-16 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US12036389B2 (en) 2020-01-06 2024-07-16 Insulet Corporation Prediction of meal and/or exercise events based on persistent residuals
WO2021163179A1 (fr) * 2020-02-11 2021-08-19 Insulet Corporation Détection de repas précoce et détection d'absorption de calories
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US20230162833A1 (en) * 2020-02-11 2023-05-25 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US12121700B2 (en) 2020-07-22 2024-10-22 Insulet Corporation Open-loop insulin delivery basal parameters based on insulin delivery records
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US12115351B2 (en) 2020-09-30 2024-10-15 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
US12128215B2 (en) 2020-09-30 2024-10-29 Insulet Corporation Drug delivery device with integrated optical-based glucose monitor
US12121701B2 (en) 2021-01-29 2024-10-22 Insulet Corporation Systems and methods for incorporating co-formulations of insulin in an automatic insulin delivery system
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
US12097355B2 (en) 2023-01-06 2024-09-24 Insulet Corporation Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation

Similar Documents

Publication Publication Date Title
WO2015056259A1 (fr) Système et procédé pour une gestion améliorée de pancréas artificiel
CN110869075B (zh) 人工胰岛系统中的胰岛素残余活性含量计算
US20240161900A1 (en) Closed loop control of physiological glucose
US20220062547A1 (en) Blood glucose control system with carbohydrate therapy indication
CN110913930B (zh) 具有自动基础和手动推注胰岛素控制的糖尿病管理系统
EP2967450B1 (fr) Système pour commande à boucle fermée d'un pancréas artificiel
US10369281B2 (en) Devices, systems and methods for adjusting fluid delivery parameters
EP2350895B1 (fr) Système et une méthode pour déterminer un profil optimal de l'insuline
RU2641976C2 (ru) Способ и система обработки ручного болюсного введения или введения в соответствии с приемом пищи в контроллерах с обратной связью
US11749408B2 (en) Individualized multiple-day simulation model of type 1 diabetic patient decision-making for developing, testing and optimizing insulin therapies driven by glucose sensors
JP2019509074A (ja) インスリン・デリバリ量の調節
US20200015760A1 (en) Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems
WO2018167727A1 (fr) Système et procédé d'amélioration de la gestion de thérapie médicamenteuse
AU2020356952A1 (en) Blood glucose control system
CN114127860A (zh) 用于确定对象的葡萄糖改变的方法和系统
Kapil et al. Artificial pancreas system for type 1 diabetes—challenges and advancements
US20230343430A1 (en) Medicament adaptation and safety monitoring
RU2778069C2 (ru) Учет остаточного количества активного инсулина в системе искусственной поджелудочной железы
US20230381414A1 (en) Assessment of past insulin delivery outcomes to automatically tune mda systems

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14854322

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 21.06.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14854322

Country of ref document: EP

Kind code of ref document: A1